After stopping Ozempic

Short answer

Semaglutide keeps weight down for as long as the drug is used. When it is stopped, weight begins to return: in the STEP 1 extension, about two-thirds of the loss was regained within a year, and values such as blood pressure and HbA1c approached baseline. In those who continued the drug, the loss was maintained. Whether stopping by reducing the dose prevents this return is not known; the exercise study summarized below on maintenance without the drug was conducted with another GLP-1 drug. This page does not recommend a decision or method for stopping; that decision is made with a physician.

Is weight regained after stopping Ozempic?

The most direct data come from the treatment-free extension of the STEP 1 trial. In STEP 1, adults without diabetes with a BMI of 30 or above (or 27 or above with a comorbidity) received a lifestyle program together with weekly semaglutide 2.4 mg or placebo for 68 weeks. At week 68, both the drug and the lifestyle program were ended, and 327 participants from centers in Canada, Germany, the United Kingdom, the US and Japan were followed for one more year. ^[1]

• Mean weight loss in the first 68 weeks was 17.3% in the semaglutide group and 2.0% in the placebo group.
• In the year after stopping, the semaglutide group regained 11.6 points of the loss and the placebo group 1.9 points.
• At week 120, the net loss from baseline was 5.6% in the semaglutide group and 0.1% in the placebo group.
• At week 120, a loss of at least 5% from baseline was maintained in 95 of 197 people (48.2%) in the semaglutide group and 21 of 93 people (22.6%) in the placebo group. ^[1]

The authors write that participants regained about two-thirds of their previous loss within a year and that this shows obesity is a chronic disease and that treatment must continue to maintain the improvements. Limitations are also stated in the publication: all analyses in the extension are exploratory, the sample is smaller than the main trial and the centers were selected from among those enrolling the most patients. Because the lifestyle program ended at the same time as the drug, it cannot be separated how much of the weight regain stems from stopping the drug and how much from stopping the program. Among the authors are manufacturer employees. ^[1]

How quickly does weight return?

A systematic review and meta-analysis published in BMJ in 2026 examined the course after discontinuation of weight management drugs in 37 studies (63 intervention arms, 9,341 participants). The mean rate of regain for all drugs was 0.4 kg per month. In the semaglutide and tirzepatide arms (10 arms, 1,776 participants), the mean loss at the end of treatment was 14.7 kg; after stopping, weight was regained at a mean of 0.8 kg per month, the estimated regain in the first year was 9.9 kg, and the model predicted return to baseline weight after about 1.5 years. ^[3]

This 1.5-year period is a model estimate: according to the authors, there are no follow-up data beyond 52 weeks for these new drugs. In the same review, weight regain after stopping the drug was 0.3 kg per month faster than after the end of behavioral weight loss programs, and this difference was independent of the size of the initial weight loss. The certainty of the evidence was rated moderate. The study is supported by NIHR and the Wellcome Trust. ^[3]

What happens to blood glucose, blood pressure and cholesterol?

In the STEP 1 extension, most of the cardiometabolic improvements seen in the first 68 weeks moved back toward baseline one year after the drug was stopped. ^[1] The observed means in the semaglutide arm are below:

Source: STEP 1 extension, Table 2; week 120 values belong to 197 participants. ^[1]

In the BMJ meta-analysis’s model, which treats all weight management drugs together, cardiometabolic markers such as HbA1c, fasting glucose, total cholesterol, triglycerides and blood pressure were also predicted to return to baseline level within 1.4 years after the drug was stopped; this estimate is not specific to semaglutide. ^[3]

In another meta-analysis examining discontinuation of GLP-1 receptor agonists, of 18 RCTs (3,771 participants), a mean weight gain of 5.63 kg and a 0.25% rise in HbA1c after stopping were found in obesity; in type 2 diabetes, a weight gain of 2.03 kg and a 0.65% rise in HbA1c. In the subgroup analysis, weight regain after semaglutide was greater than after liraglutide (8.21 kg versus 4.29 kg). Heterogeneity between studies in the weight and HbA1c results in obesity was very high (I² above 98%). ^[4]

The Turkish patient information leaflet for Ozempic states that blood glucose levels may rise if the drug is stopped and that the drug should not be stopped without talking to the doctor. ^[9] Because in type 2 diabetes Ozempic is part of a glycemic treatment, stopping needs to be planned together with the rest of the diabetes treatment.

What difference does continuing the drug make?

STEP 4 tested this question in a randomized fashion. In 803 adults who lost a mean of 10.6% of weight in a 20-week open-label semaglutide period and reached 2.4 mg, participants either continued semaglutide or switched to placebo for 48 weeks; lifestyle support was given to both groups. Weight change from week 20 to week 68 was −7.9% in those continuing semaglutide and +6.9% in those switched to placebo (difference −14.8 points). Digestive side effects were reported in 49.1% of those continuing and 26.1% of those switched to placebo; discontinuation rates because of side effects were similar (2.4% versus 2.2%). ^[2]

SURMOUNT-4, conducted with tirzepatide from the same class, showed a similar picture: in 670 people who lost a mean of 20.9% of weight with 36 weeks of treatment, over the next 52 weeks those continuing tirzepatide lost a further 5.5% while those switched to placebo gained 14.0%. ^[5]

Detailed guideTirzepatide: the GIP/GLP-1 dual agonist→

Does stopping by reducing the dose work?

This question has not yet been answered. A 2026 review summarizes that weight regain after stopping is concentrated most in the first months and that this may be related to several mechanisms, such as the return of appetite signals and a rise in hunger hormones. The review mentions new randomized data suggesting that maintenance with lower-intensity drug may reduce regain compared with abrupt stopping; however, it emphasizes that it is not known whether structured dose reduction (tapering) strategies successfully make stopping treatment easier and that this needs to be tested in prospective studies. ^[7]

The Turkish SmPC (KÜB) contains no scheme for stopping semaglutide by gradual reduction; the dose steps in the SmPC are only for initiation and escalation. ^[8]

Which drug-free maintenance strategies have been studied?

A study examining the role of exercise after drug discontinuation in a randomized design was conducted in Denmark with liraglutide, another GLP-1 receptor agonist. Adults with obesity who lost a mean of 13.1 kg on an 8-week low-calorie diet were divided into groups of supervised exercise for one year, liraglutide 3.0 mg daily, the two used together, or placebo; one year after treatment ended, 109 participants were reassessed. ^[6]

• In the year after treatment ended, weight regain was 6.0 kg greater in the group in which liraglutide was stopped than in the group in which exercise was stopped.
• Those who had taken exercise and liraglutide together were 5.1 kg lower in weight than those who had taken liraglutide alone, up to one year after randomization.
• The authors interpret that adding supervised exercise to drug treatment improved maintenance of weight after stopping and that weight and body composition were maintained in the exercise group. ^[6]

This study was conducted with liraglutide, follow-up participation was partial, and it was supported by a foundation connected to the manufacturer and by Helsefonden; the results cannot be carried directly over to semaglutide. ^[6]

When does semaglutide leave the body?

According to the Turkish SmPC, the elimination half-life of semaglutide is about one week and it remains in the circulation for about five weeks after the last dose. For the same reason, the SmPC states that the drug should be stopped at least two months before a planned pregnancy. ^[8] In the STEP 1 extension, post-discontinuation measurements were made at weeks 75, 80, 104 and 120. ^[1]

Detailed guideSemaglutide (Ozempic, Wegovy, Rybelsus): evidence and safety→ Detailed guideOzempic side effects: frequencies, serious warnings and unknowns→ Detailed guideHow is Ozempic used? Administration information in the SmPC (KÜB)→ Detailed guideGLP-1 agonists: the class, its members and licensing status in Türkiye→

Which warnings apply during treatment and when stopping?

The decision to stop does not remove the drug’s safety profile. The Turkish SmPC lists a personal or family history of medullary thyroid cancer and MEN 2 syndrome as contraindications; it states that it should not be used in pregnancy and breastfeeding and that it should be stopped at least two months before a planned pregnancy. ^[8] In Türkiye, a letter from the Erzurum Provincial Health Directorate to the pharmacists’ chamber (chamber registration date May 20, 2026), referring to the TİTCK (Turkish Medicines and Medical Devices Agency) letter dated May 14, 2026, relays that reports of suspected counterfeiting of medicines containing GLP-1 receptor agonists have increased markedly; in pharmacy and pharmaceutical warehouse inspections, Ozempic, Saxenda and Wegovy pens and Mounjaro solution for injection are stated to carry a high counterfeit risk. The letter emphasizes that medicines should not be bought over the internet and that medicines that cannot be registered in the Medicine Track and Trace System (İTS) should not be kept or used. ^[10]

Limits of this page

This page summarizes studies showing what happens when semaglutide and similar drugs are stopped. It gives no recommendation on continuing the drug, stopping it, reducing the dose or substituting another program. Most of the studies were conducted in adults with obesity without diabetes and with manufacturer support; in type 2 diabetes, the decision to stop is assessed by a physician together with the whole of diabetes treatment.